Health Catalyst vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
$307M revenue 2024 (up from $296M 2023); $316M TTM Jun 2025; $26M adjusted EBITDA; 100M+ patient records; expects double-digit growth 2025; low-20s net new platform clients 2024; healthcare analytics leader
About
Health Catalyst is a healthcare data and analytics company founded in 2008 in Salt Lake City, Utah, built on the mission of being a catalyst for massive, measurable, data-informed improvement in the health of humanity. The company's core technology — the Health Catalyst Data Operating System (DOS) — provides healthcare organizations with a cloud-based data platform that aggregates clinical, financial, and operational data from disparate source systems into a unified analytics environment designed specifically for the complexity of healthcare data.\n\nHealth Catalyst serves 40+ health systems and hundreds of hospitals, offering analytics applications, embedded data science teams, and technology-enabled services that help organizations improve quality outcomes, reduce costs, and optimize operations. Its suite includes applications for perioperative efficiency, population health management, sepsis surveillance, and financial analytics. The company differentiates through a unique Tech-Enabled Managed Services model, embedding data scientists alongside health system teams to ensure analytics drive measurable operational change rather than sitting unused.\n\nHealth Catalyst generated $307M in revenue in 2024, up from $296M in 2023, with $26M in adjusted EBITDA and a database of over 100 million patient records. As a publicly traded company (HCAT), it has built one of the largest healthcare-specific analytics platforms in the US. With regulatory pressure, value-based care contracts, and margin compression intensifying across health systems, Health Catalyst's integrated data platform and domain expertise position it as a strategic partner for health systems pursuing data-driven operational transformation.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.